Search research articles
Contact Us
Filters
Showing results (51-60 of 143) with videos related to
Page
of 15
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN
|
October 2, 2009
Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II
Owen O'Connor, John Wright, Craig H Moskowitz, et al.
Blood
|
August 11, 2005
Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL
Craig H Moskowitz, Andrew D Zelenetz, Tarun Kewalramani, et al.
Blood
|
May 12, 2017
Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma
Pier Luigi Zinzani, Vincent Ribrag, Craig H Moskowitz, et al.
Leukemia & Lymphoma
|
July 11, 2012
Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma
Andres Forero-Torres, Nancy Bartlett, Anne Beaven, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
October 8, 2016
A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning
Michael Scordo, Valkal Bhatt, Meier Hsu, et al.
British Journal of Haematology
|
August 24, 2005
Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999
Paul A Hamlin, Carol S Portlock, David J Straus, et al.
Blood
|
March 12, 2015
Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma
Craig S Sauter, Matthew J Matasar, Jessica Meikle, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM
|
November 24, 2004
Differential expression patterns of c-REL protein in classic and nodular lymphocyte predominant Hodgkin lymphoma
Qianxun Xiao, Ning Shen, Cyrus V Hedvat, et al.
British Journal of Haematology
|
July 6, 2016
Risk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation
Gunjan L Shah, Joachim Yahalom, Matthew J Matasar, et al.
British Journal of Haematology
|
February 6, 2016
The potential benefit of allogeneic over autologous transplantation in patients with very early relapsed and refractory follicular lymphoma with prior remission duration of ≤12 months
Matthew A Lunning, Jocelyn C Migliacci, Patrick Hilden, et al.
Page
of 15
Search research articles
Search
Showing results (51-60 of 143) with videos related to
Sort By:
Page
of 15
Journal of the National Comprehensive Cancer Network : JNCCN
|
October 2, 2009
Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II
Owen O'Connor, John Wright, Craig H Moskowitz, et al.
Blood
|
August 11, 2005
Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL
Craig H Moskowitz, Andrew D Zelenetz, Tarun Kewalramani, et al.
Blood
|
May 12, 2017
Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma
Pier Luigi Zinzani, Vincent Ribrag, Craig H Moskowitz, et al.
Leukemia & Lymphoma
|
July 11, 2012
Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma
Andres Forero-Torres, Nancy Bartlett, Anne Beaven, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
October 8, 2016
A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning
Michael Scordo, Valkal Bhatt, Meier Hsu, et al.
British Journal of Haematology
|
August 24, 2005
Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999
Paul A Hamlin, Carol S Portlock, David J Straus, et al.
Blood
|
March 12, 2015
Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma
Craig S Sauter, Matthew J Matasar, Jessica Meikle, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM
|
November 24, 2004
Differential expression patterns of c-REL protein in classic and nodular lymphocyte predominant Hodgkin lymphoma
Qianxun Xiao, Ning Shen, Cyrus V Hedvat, et al.
British Journal of Haematology
|
July 6, 2016
Risk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation
Gunjan L Shah, Joachim Yahalom, Matthew J Matasar, et al.
British Journal of Haematology
|
February 6, 2016
The potential benefit of allogeneic over autologous transplantation in patients with very early relapsed and refractory follicular lymphoma with prior remission duration of ≤12 months
Matthew A Lunning, Jocelyn C Migliacci, Patrick Hilden, et al.
Page
of 15